negative percentage of volume? Dont know what you are refering to here.
And .25 is not a fat premium for the seller. Options were done at a quarter when market was .15 x .25. They where bought.
Volume in the june 10's also.
Teach, please teach me how Nite, who was bidding(wanting to buy) for 10k shares yesterday at .41, sold to itself(shorted) those 10k. What you say discounts any knowledge as to how the markets work. Today again, nite on bid at .42 and was hit.
The correct inference here is that nite is BUYING shares, testing the bid, trying to cover at the lowest price possible before results. They has been unsuccessful in breaking trading range to the down side, where they really wanted to buy, so now buying slowly.
"appears to be short by nite." ??? They were bidding, how in the heck can anyone tell who seller was. Come on. Nite on bid is a huge signal that they want to cover. You dont bid shares and then buy and call that a short. What the heck????????????????????? This board gets better all the time.
yes, i am sure its was always the plan to design a P3 trial with Ora and the Koreans, that would purposely miss 2 primary endpoints, so that JJ and Goldstein and McNay could steal assets from investors(which, by the way, include the 3 named principals and the Koreans).
I get the wait is frustrating for all, its clear there is little of value in most of the posts here. Come on bull, board doesnt need another sno.
For sure, when positive trial results posted, the 2018 timeline will be meaningless in terms of getting money. And at a much higher level than 40 cents.
Investors here have been more than patient. It is time for some type of update on china deal or trial news. Lets go for goodness sake............................................
Even reseller couldnt let that superb management comment go. PJ, are you on dope? Please give us some tangible examples of how managements decision making in the last 3+ years has benefited shareholders(higher stock price)
Ma has allowed castle and leiberman to rape this company and its shareholders. Watch the cash balance in the upcoming report.
What are you talking about...."merger of equals." No premium. First you say no stock deal for rgrx, and if a stock deal no premium, and maybe cash deal at market cap price. ?
gtree for rgrx? How can that be called a merger of equals? By definition, thats impossible. A deal would be for a certain ratio of gtree stock....thats the currency. And jj is not going to approve a no premuim stock deal. That is just silly. Gtree could easily offer 100 million worth of their stock for rgrx. RGRX would get a nice pop and still be able to hang on to the new shares and get benefit of further appreciation in TB4 market. But, the phrase merger of equals has no application here. And its becoming more attractive for any korean company to have a US listing and possible domicile as North Korean gets more crazed and dangerous.
And i would think the last indication of value here is the heart indication. That is 100's of millions of trial expense, to say nothing of the fact that rgrx cant even produce it for a trial as FDA halted production of that a while back. They need a whole new qualified producer.
Sno you continue to pontificate about rgrx. Most is a muted negative bias that has little bases in fact. You dont know JJ, 2 is more than 40 cents, market size, takeover structures, trial success potential and rgrx stocks reaction...............It just goes on and on. Stick to research as time and time again your opinions are just 100% incorrect.
Man, all the whinning about how stock should be at this level or that level. Perfect wave? Hang ten. A triangle? You think an illiquid, unfollowed bb stock is bound by silly chart obsevations? Outsized stock market returns do not accomodate the masses. I have yet to be on a board with a decent following that doesnt have shareholders screaming about market manipulation. Its just the way the markets are.
Trials will succeed and stock will react accordingly. If any dont believe that, they should sell. Trying to read the stock action tea leaves here is a fools errand.
There is only one regret shareholders who have been here for years will have in a couple months, and that is looking back a saying why didnt i buy more when stock was stuck in this trading range.
Its a strange world investors of rgrx have lived in since july; just one long, tight trading range. And all this, while gtree(a rgrx proxy) has gone parabolic. I have talked to a couple foreign trading desks at some big house and asked them about the Korean markets. Are they prone to illegal pump and dump. And all say that Korean markets are legit and not like some 3rd world markets. In fact, many say that type of scheme is more seen in US. So, while anything is possible, gtree and their management have a history, and markets there are decent, so i dont see a pump and dump there.
As far as rgrx trading, i think its a function of very illiquid, low priced, cash poor, BB market stock and a highly unusual pending trial that will make or break company. Many of my smaller stocks are seeing low volume, as interest and players here seemed to have dried up. I have never seen such a low priced bio with no cash and no employees, have such a late stage, big market trial up in the next month or so. Anyone doing DD would just see decades of failure and finance needs. And a JV agreement few understand. Why play before results? We here are either the fortunate few who are about to be richly rewarded for our patience and seeing what others cant, or..........
I say early dry eye trials have led to easily attainable P3 endpoints with a much more receptive FDA in this indication. And, trial fully funded and done by best in class.....Ora.
Its an interesting thought. So far, zika is confronted with either a vaccine or irradiation or genetic modification of male mosquitos. No one has presented a possible MOA that you have presented. If, any preclincal study was done using TB4 to treat Zika, naming rgrx, you would see a massive spike. Zika is the headline of the day in the bioworld.
Anyone selling on that PR is nuts. Trial on time and 1000's of data points have to be analysed. Will it take till June for any data to come out? Not likely. JJ has hinted we will see data way before June. All you have to do is watch gtree stock. Koreans are seeing data and stock is reacting accordingly. I would expect a 1 miilion+ day in gtree with 10% or better gains there to be the real tell.
Also clear, as i said, Koreans do things on their own. If JJ had this pr(if koreans had told him ahead of time) he would have issued a PR. Between the language barrier, distance, and general Asian business attitude of "only we matter," I would expect trial results to be announced by koreans before rgrx even gets details. IMHO...........No matter, jj has final say on any deal resulting from positive results.
As usual, nite takes advantage of this unknown stock called rgrx. They can push around price as they wish. In the end( very soon), it will not matter. Watch gtree for the real deal.
Price action in Gtree yesterday was very telling. Stock had a little profit taking at the opening but then finished on the HOD. Are they seeing good data?
I was not questioning your ownership. My posts were directed at sno and his silly satisfaction with a 40 cent price vs a 2 dollar price....just amazing.
Sno, there obviously isnt much to say as we wait for results. You should just be quiet. That was just an idiot post spoken by someone who could only own very few shares...........good luck
Below is the most convoluted logic i have ever seen
I'm actually GLAD that we are in low 40 cents. because if trial flops, we only have a few dimes to lose. Other stocks that get "noticed and hyped" run way up on Phase 3 hoped for news. But if it fails, you have a LOT lower to go and lose. Imagine if RGRX was hyped and all knew about it.....and anticipation of Phs 3 got us to $1.50 or $2.00. if the trial flopped and most of us have SIX figures of numbers of shares, a drop of $1.50 would be a killer. But a drop of a few dimes from 40 cents? That won't hurt as bad. And if trial wins, it will be MUCh sweeter to start from 40 cents and skyrocket!. .
This drug does little to help ALS patients and provides nothing but a false hope.: another month of struggle?
And many primary endpoints are subjective. Just look at dry eye trials at shire.
Anyway my main point here was that management has delivered little to shareholders and yet they feel entilted to bonus and big salaries? Give me a break. I am so sick of little bio's run by managements that are not aligned with the owners.
Amgn is the only hope for this company.